Prolongation of Survival of Nude Mice Bearing Human Colon Cancer

Hyams, David M.; Esteban, José M.; Beatty, Barbara; Wanek, Philip M.; Beatty, J. David

doi:10.1001/archsurg.1989.01410020045007

Cited by 12 publications

(2 citation statements)

References 10 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prolongation of the survival of nude mice bearing colon carinoma xenografts by administration of 120 MCi of 9Y-ZCE025 (anti-CEA antibody) has also been reported (Hyams et al, 1989). The median survival was doubled in comparison with the mice treated with the radiolabelled non-specific antibody.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)

Antoniw

Farnsworth²,

Turner³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

“…Several studies on the therapeutic efficacy in mouse models of monoclonal antibodies labelled with 90Y via acyclic chelators such as DTPA have been reported previously (Hyams et al, 1989;Lee et al, 1990;Washburn et al, 1991;Buras et al, 1993). In these studies growth delay of colorectal carcinoma xenografts and improved survival of mice were demonstrated.…”

mentioning

confidence: 96%

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)

Antoniw

Farnsworth²,

Turner³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

Radioimmunotherapy of Human Colon Cancer in Nude Mice

Buras

Beatty²,

Williams³

et al. 1990

Arch Surg

View full text Add to dashboard Cite

Immunotherapy of colorectal cancer

Beatty¹

1992

Cancer

View full text Add to dashboard Cite

Specific and nonspecific stimulation of the host immune system to reject cancer is an attractive concept that is just beginning to mature. Results with crude extracts and nonspecific immune stimulation have been variable. However, the recent observations of improved survival after administration of levamisole plus 5‐fluorouracil in the adjuvant setting have made an impact on the treatment of colorectal cancer. Animal studies consistently show that immune therapies are most effective for disease that is not advanced. Thus, the small benefit seen with levamisole, a low toxicity immunomodulator, suggests that much more impressive results can be anticipated with more potent and specific agents. Postsurgical autologous tumor cell vaccine has been effective in some prospective randomized trials; in others, no benefit was found. The identification and purification of allogeneic tumor‐associated antigens has lead to enhanced antigen‐specific host cell‐mediated immunity; this may result in more consistent antitumor effects. The current development of chemically defined immune adjuvants of low toxicity allows tumor‐specific immune stimulation to be tested in high‐risk apparently healthy patients after resection of colorectal cancer (Stages II and III). The influx of information regarding immune cell populations, cell‐surface markers, and cytokines has fostered extensive exploration of lymphocyte stimulation, in vitro cell growth and expansion, and in vivo evaluation in patients with advanced cancer. Modest tumor response rates have been documented with adoptive transfer of lymphokine‐activated killer cells and interleukin‐2. Improved results are anticipated with the more potent tumor‐infiltrating lymphocytes and specific in vitro sensitization of draining lymph node cells to autologous and allogeneic tumor antigens. Murine monoclonal antibodies specific for cell‐surface markers, such as carcinoembryonic antigen, have been tested for their value in the diagnosis and therapy of colorectal cancer. A small response rate has been seen with single and multiple injections of C017–1A, a monoclonal antibody specific for colonic and pancreatic cancer. The development of antiidiotypic antibodies in these patients may have been important in those that responded to this type of therapy. However, laboratory evidence suggests that monoclonal antibody conjugated to a cytotoxic agent (i.e., radionuclide, drug, or toxin) should be much more effective. Radioimmunotherapy trials in the nude mouse model bearing human colon cancer xenografts showed good tumor incorporation of the radionuclide (yttrium 90 or iodine 131), inhibition of tumor growth, and long‐term survival. A combination of such therapy with (1) cytokines to enhance antigen expression and (2) cytotoxic drugs has lead to improved antitumor effects. The major hazard of radioimmunotherapy is hematologic toxicity. Bone marrow transplantation has permitted investigators to double the dose and augment the efficacy of this type of treatment. Clinical trials of radioimmunotherapy...

show abstract

Prolongation of Survival of Nude Mice Bearing Human Colon Cancer

Cited by 12 publications

References 10 publications

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)

Radioimmunotherapy of Human Colon Cancer in Nude Mice

Immunotherapy of colorectal cancer

Contact Info

Product

Resources

About